Category: 2020

December | 2020

Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package

TEL AVIV, Israel and BETHESDA, Maryland, Dec. 21, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. Dec 21, 2020, 09:27 ET (OTCQB: CNBX), a globa

November | 2020

Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors

Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors Nov 16,

November | 2020

Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33

TEL AVIV, Israel and BETHESDA, Md., Nov. 9, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related can

October | 2020

Cannabics Pharmaceuticals receives “Intention to Grant a European Patent” notice for its System and Method for High Throughput Screening of Cancer Cells patent application

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer relat

October | 2020

Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

TEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related ca

August | 2020

Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33

TEL AVIV, Israel and BETHESDA, Maryland, Aug. 20, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

August | 2020

Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors

TEL AVIV, Israel and BETHESDA, Md., Aug. 5, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on

July | 2020

Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets

TEL AVIV, Israel and BETHESDA, Maryland, July 14, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

June | 2020

Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, June 16, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

June | 2020

Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

TEL AVIV, Israel and BETHESDA, Maryland, June 10, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

May | 2020

Cannabics Pharmaceuticals to Capitalize on Israel’s Final Approval for the Export of Medical Cannabis

TEL AVIV, Israel and BETHESDA, Maryland, May 26, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focus

May | 2020

Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids

TEL AVIV, Israel and BETHESDA, Maryland, May 6, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focu

April | 2020

Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, April 27, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine foc

April | 2020

Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer

TEL AVIV, Israel and BETHESDA, Maryland, April 13, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine foc

March | 2020

Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids

TEL AVIV, Israel and BETHESDA, Maryland, March 25, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine foc

March | 2020

Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research

TEL AVIV, Israel and BETHESDA, Maryland, March 18, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine foc

March | 2020

Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

TEL AVIV, Israel and BETHESDA, Maryland, March 11, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabino

March | 2020

Cannabics Pharmaceuticals Reveals Different Extraction Methods Result in Differential Necrotic Effects of Cannabis on Gastrointestinal Cancer Cells

TEL AVIV, Israel and BETHESDA, Maryland, March 2, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabin

February | 2020

Cannabics Pharmaceuticals Partners With NewCanna to Commence Research Based on Colombian Indigenous Cannabis Landraces

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 25, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabin

February | 2020

Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 18, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoi

February | 2020

Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 11, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoi

January | 2020

Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit

TEL AVIV, Israel and BETHESDA, Maryland, Jan. 27, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoi

January | 2020

Cannabics Pharmaceuticals Announces Cannabigerol (CBG) Shown to Have Anti-tumor Properties

TEL AVIV, Israel and BETHESDA, Maryland, Jan. 9, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid